Akeso's Recent Milestone in Cancer Research
Akeso Inc. (9926.HK) has marked a significant moment in cancer treatment with the dosing of its first patient in a pivotal Phase II clinical study. This trial, referred to as AK130-202, is focused on the development of AK130, a pioneering TIGIT/TGF-? bifunctional antibody fusion protein, used in combination with ivonescimab for patients facing advanced pancreatic cancer.
Innovative Treatment Approach
AK130 stands out as the world's first TIGIT/TGF-? bifunctional antibody fusion protein to advance into registrational clinical development. The initiation of the AK130-202 trial embodies Akeso's commitment to integrating cutting-edge immuno-oncology strategies. This approach leverages combination therapies that represent Akeso's leadership in the evolving field of immunotherapy.
Enhancing Combination Therapies
To date, Akeso has developed nine proprietary bispecific antibodies or bispecific antibody-drug conjugates (ADCs) that are currently in clinical trials or have received regulatory approval. The company’s innovative bispecific antibody technology platform supports the development of advanced combination therapies involving established treatments, like ivonescimab, and promising candidates such as AK130 and AK146D1, which targets tumors through a unique mechanism.
Synergistic Potential of AK130
Preclinical findings highlight the therapeutic potential of concurrently targeting the PD-1/VEGF and TIGIT/TGF-? pathways. This dual blockade approach aims to alter the tumor immune microenvironment favorably, fostering better anti-tumor responses. The previous clinical data regarding ivonescimab treatment alone in pancreatic cancer indicates a strong efficacy, suggesting that combining it with AK130 could yield improved therapeutic outcomes for patients battling this aggressive cancer.
Dive into AK130’s Mechanism
AK130 is designed as a bifunctional antibody fusion protein that merges an anti-TIGIT monoclonal antibody with the extracellular domain of the human TGF-? receptor II. By blocking the TIGIT-CD155 interactions, this innovative treatment may enhance the activity of CD8+ T cells and natural killer (NK) cells against tumors. In addition, it seeks to address the immunosuppressive actions facilitated by TGF-? signaling, providing a two-fold approach to strengthen patient immune responses against tumors.
Future Studies on AK130
As this groundbreaking fusion protein begins its journey in the AK130-202 study, further clinical investigations are planned. These will assess AK130 not only in combination with ivonescimab for advanced pancreatic cancer but also as a monotherapy targeting other solid tumors. This broadens the prospects for patients suffering from various advanced malignancies and underscores Akeso's commitment to delivering innovative treatments.
About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical innovator dedicated to the research, development, manufacturing, and commercialization of groundbreaking biological medicines. Founded in 2012, Akeso has established a unique integrated research and development system alongside an advanced platform for bispecific antibody drug development. Today, Akeso boasts over 50 innovative assets targeting major diseases, including cancer, autoimmune disorders, and metabolic illnesses. With 24 candidates in clinical trials, including 15 bispecific/multispecific antibodies, Akeso is focused on providing accessible and effective treatments to patients worldwide, further establishing its position as a global biopharmaceutical leader.
Frequently Asked Questions
What is AK130?
AK130 is a TIGIT/TGF-? bifunctional antibody fusion protein developed by Akeso, targeting advanced pancreatic cancer.
How does AK130 work?
It works by blocking TIGIT and TGF-? interactions, enhancing immune responses against tumors.
What is the purpose of the AK130-202 study?
The study aims to evaluate the safety and efficacy of AK130 in combination with ivonescimab for patients with advanced pancreatic cancer.
What other treatments is Akeso developing?
Akeso is working on various bispecific antibodies and ADCs for different cancers and diseases, with several in clinical trials.
Why is this study significant?
This study represents a new direction in cancer treatment, exploring innovative therapies that could significantly impact patient outcomes.
